Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma.
EPI-2010 is a respirable antisense oligonucleotide (RASON), which selectively attenuates discordantly overexpressed adenosine A(1) receptors in allergic lung (Nature 1997;385:721). In the present study, aerosolized [(35)S]-labeled EPI-2010 (5 mg exposure; specific activity 0.055 Ci/mmol) was administered to normal rabbits by endotracheal tube to assess biodistribution, route of elimination, and potential cardiovascular toxicity. The animals were killed at 0, 6, 24, 48, and 72 h after inhalation of EPI-2010. Duplicate aliquots from different tissues and samples were solubilized and assessed for radioactivity. Approximately 1.4% of the total aerosolized EPI-2010 was deposited into the lung. The concentration of the drug in the lung at 0, 6, 24, 48, and 72 h was 64.0 +/- 1.5, 67.0 +/- 4.4, 32.0 +/- 3.7, 23.4 +/- 1.4, and 2.1 +/- 0.5 microg equivalents, respectively. Only a small amount of the radioactivity was detected in extrapulmonary tissues. By 72 h, 67.5% of the administered dose was excreted in the urine, which represented the major pathway of elimination. In postlabeling studies, intact full-length EPI-2010 could only be detected in the lung. Autoradiographic analysis after inhalation of [(35)S]-labeled EPI-2010 showed a relatively uniform deposition of drug throughout the lung. The aerosolized EPI-2010 did not have any significant systemic effects on the cardiovascular system as determined by Cardiomax-II analysis. This pattern of distribution and the lack of effect on cardiovascular function support the concept that RASONs offer the potential to safely address respiratory targets for which systemic distribution and systemic bioavailability may be contraindicated.
Department of Molecular Pharmacology and Therapeutics, EpiGenesis Pharmaceuticals Inc., Princeton, New Jersey 08512, USA.
S
S
Ali
S A
SA
Leonard
C A
CA
Kukoly
W J
WJ
Metzger
W R
WR
Wooles
J F
JF
McGinty
M
M
Tanaka
A
A
Sandrasagra
J W
JW
Nyce
D000280:Administration, Inhalation; D000704:Analysis of Variance; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D004195:Disease Models, Animal; D005243:Feces / Q000737:chemistry; D005260:Female; D006321:Heart / Q000187:drug effects; D008168:Lung / Q000378:metabolism; D008297:Male; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D010710:Phosphates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D011336:Probability; D011817:Rabbits; D012680:Sensitivity and Specificity; D014556:Urine / Q000737:chemistry
D018927:Anti-Asthmatic Agents; C425883:EPI2010; D016376:Oligonucleotides, Antisense; D010710:Phosphates